Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context
Key Highlights
- ➤Palantir (PLTR) Q2 revenue $1.935B, up 93% year over year
- ➤Palantir raised full-year revenue guidance to $8.150B-$8.158B
- ➤Snowflake (SNOW) Q2 product revenue $1.49B, up 37% year over year
- ➤Microsoft (MSFT) fiscal Q4 revenue $90.0B, up 18%; Azure grew 43%
- ➤Veeva (VEEV) raised full-year revenue guidance to $3.682B-$3.687B
Expert Statements
Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk
“The enterprise has discovered that an agent without an ontology guesses, and a guessing agent is a liability. That is exactly right, and it is exactly half of pharma’s problem”
Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk
“An enterprise ontology tells an agent what a purchase order, a patient or a clinical site is. In our view it cannot tell an agent what a protein does, which regions of an antibody biology will tolerate, or why a program that failed three years ago matters to the one running today.”
Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk
“The competitive question is no longer which model or agent you run; every model becomes commodity. The question is what the model or agent runs on, because that is where the value ends up”
Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk
“In the enterprise, that is an ontology of the business. In biology, it has to be a representation of biology itself, built from what evolution preserved, and the customer’s own programs, including the ones that failed, have to keep compounding inside it.”
Alex Karp, Co-Founder and Chief Executive Officer of Palantir Technologies
“Demand for AI sovereignty has now been unleashed. And Palantir is the only company that has demonstrated it can transform tokens into actual economic value,”
Sridhar Ramaswamy, Chief Executive Officer of Snowflake
“The Agentic Enterprise runs on Snowflake, and we’re just getting started,”
Satya Nadella, Chairman and Chief Executive Officer of Microsoft
“This year, Azure revenue surpassed $100 billion for the first time, and Microsoft 365 Copilot reached over 30 million paid seats,”
Peter Gassner, Chief Executive Officer of Veeva Systems
“AI is opening up the next big chapter for Veeva and life sciences”
AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The global market for artificial intelligence in drug discovery is projected to grow from $5.09 billion in 2026 to $17.56 billion by 2031, a compound annual growth rate of 28.1%, according to MarketsandMarkets. As that spending moves from pilots into discovery workflows, the enterprise software industry has converged on a new layer between an organization’s data and the AI agents that act on it, variously called an ontology, a semantic layer or a context layer. The open question for life sciences is whether a layer built to describe a business can also describe biology. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), Palantir Technologies Inc. (NASDAQ: PLTR), Snowflake Inc. (NYSE: SNOW), Microsoft Corporation (NASDAQ: MSFT), Veeva Systems Inc. (NYSE: VEEV).
Get started
Create a free account to read the full story.